QCG
AQST icon

Quadrant Capital Group’s Aquestive Therapeutics AQST Stock Holding History

Quadrant Capital Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-168
Closed -$488 – 1409
2025
Q1 		$488 Buy
+168
New +$509 ﹤0.01% 2668

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Quadrant Capital Group's AQST Position: Q2 2025 in Review

Quadrant Capital Group sold out of Aquestive Therapeutics (AQST) in Q2 2025, closing a stake of 168 shares — an estimated $488 sold.

Quadrant Capital Group first reported a position in AQST in Q1 2025 and held it in 1 quarter. The position peaked at $488 in Q1 2025. 116 funds tracked by Wall St. Rank hold AQST as of Q2 2025.

  • Quadrant Capital Group reported no remaining Aquestive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 168 Aquestive Therapeutics shares in Q2 2025, an estimated $488.
  • Quadrant Capital Group first reported a position in Aquestive Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quadrant Capital Group's Aquestive Therapeutics position peaked at $488 in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.